Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.70 |
| ▸ | RXRB | P28702 | 2/20 | 0.70 |
| ▸ | RXRG | P48443 | 2/20 | 0.70 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71773 | 0.88 | PARP10 (0.59) | RXRARXRBRXRGPTGER1NPC1 | |
| SCHEMBL71526 | 0.88 | RXRA (0.58) | RXRARXRBRXRGMRGPRX4NR4A2 | |
| SCHEMBL13440174 | 0.88 | RXRA (0.70) | RXRARXRBRXRGMRGPRX4NR4A2 | |
| SCHEMBL69503 | 0.87 | RXRA (0.57) | RXRARXRBRXRGKMT2ANPC1 | |
| SCHEMBL31241237 | 0.87 | LMNA (0.59) | RXRARXRBRXRGMRGPRX4MEN1 | |
| SCHEMBL16929834 | 0.87 | LMNA (0.59) | RXRARXRBRXRGMRGPRX4MEN1 | |
| SCHEMBL1600077 | 0.85 | MRGPRX4 (0.62) | RXRARXRBRXRGMRGPRX4NR4A2 | |
| SCHEMBL29556736 | 0.85 | MRGPRX4 (0.62) | RXRARXRBRXRGMRGPRX4NR4A2 | |
| SCHEMBL27472542 | 0.84 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4MEN1 | |
| SCHEMBL2786958 | 0.84 | NPC1 (0.55) | RXRARXRBRXRGMRGPRX4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2020-07-02 | — | — | US | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3099685-B1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9458153-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| WO-2010026095-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-5677112-A | USING AN ANTHRACENE COMPOUND | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0635480-B1 | Anthracene derivatives | WAKO PURE CHEM IND LTD (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5576359-A | ANTHRACENE DERIVATIVE, SOLVENT, COMPOUND CONTAINING GLYCIDYL GROUPS | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0636941-B1 | Deep ultraviolet absorbent and its use in pattern formation | WAKO PURE CHEM IND LTD (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5498748-A | PHENOLIC CROSSLINKER FOR A POLYGLYCIDYL METHACRYLATE TO FORM A MATERIAL USED AS AN ANTIREFLECTION COATING FOR DEEP UV LIGHT SUCH AS KRF EXIMER LASERS IN SEMICONDUCTOR PHOTORESISTS | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0636941-A1 | Deep ultraviolet absorbent and its use in pattern formation | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1995-02-01 | — | — | EP | disclosed |
| EP-0635480-A1 | Anthracene derivatives | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK7, PCSK6 | RXRA 1184/4885RXRB 1117/4885RXRG 1072/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | RXRA 1461/4885RXRB 1194/4885RXRG 1087/4885 |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | RXRA 990/4885RXRB 375/4885RXRG 1074/4885 |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | RXRA 1184/4885RXRB 1117/4885RXRG 1072/4885 |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, DHX15 | RXRA 990/4885RXRB 375/4885RXRG 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.